Chun K A, Cho I H, Won K C, Lee K H, Lee H W, Hyun M S, Hayashida K
Department of Nuclear Medicine, Yeungnam University Hospital, Taegu, Korea.
Clin Nucl Med. 2001 Mar;26(3):212-5. doi: 10.1097/00003072-200103000-00006.
The authors report abnormal Tc-99m sestamibi (MIBI) and TI-201 uptake in a 62-year-old patient with histologically and biochemically proved myeloma. TI-201 imaging was undertaken for tumor evaluation, and 3 days later a Tc-99m MIBI study showed diffuse and focal marrow uptake with focal skull lesions, whereas TI-201 did not show skull lesions. After treatment, follow-up Tc-99m MIBI whole-body imaging was performed and the marrow uptake was decreased.
作者报告了一名62岁经组织学和生化检查证实为骨髓瘤的患者，其锝-99m甲氧基异丁基异腈（MIBI）和铊-201摄取异常。进行铊-201显像以评估肿瘤，3天后的锝-99m MIBI研究显示弥漫性和局灶性骨髓摄取以及颅骨局灶性病变，而铊-201未显示颅骨病变。治疗后，进行了锝-99m MIBI全身显像随访，骨髓摄取减少。
